Table 7. Mutagenic activity expressed as the mean and standard deviation of the number of revertants and mutagenic index (MI) (in brackets) in strains TA98, TA100, TA102 and TA97a exposed to SCAR01 at various doses, with (+S9) or without (-S9) metabolic activation.
| Treatment Number of revertants (M ± SD)/plate and MI | ||||||||||
| µg/plate | TA 98 | TA 100 | TA 102 | µg/plate | TA 97a | |||||
| −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | |||
| SCAR01 | 0.00 a | 17±3 | 40±2 | 114±12 | 145±5 | 352±24 | 300±21 | 0.00 a | 107±13 | 114±15 |
| 18.8 | 19±2 (1.1) | 40±4(1.0) | 135±15(1.2) | 138±10 (0.9) | 333±34 (0.9) | 338±18 (1.1) | 6.25 | 111±10 (1.0) | 131±13 (1.2) | |
| 37.5 | 21±2 (1.2) | 40±4(1.0) | 115±31(1.0) | 146±12(1.0) | 299±29 (0.8) | 283±24 (0.9) | 12.5 | 116±21 (1.1) | 98±22(0.9) | |
| 75 | 18±3 (1.0) | 39±7 (1.0) | 125±19(1.1) | 145±16 (1.0) | 351±52 (1.0) | 299±45 (1.0) | 25 | 100±17 (0.9) | 128±18 (1.1) | |
| 112.5 | 18±4 (1.0) | 40±9 (1.0) | 127±10 (1.1) | 141±10 (1.0) | 301±35 (0.9) | 323±49 (1.1) | 37.5 | 93±12 (0.9) | 94±28 (0.8) | |
| 150 | 15±2 (0.9) | 37±2 (0.9) | 136±13(1.2) | 114±19(0.8) | 361±42 (1.0) | 312±20 (1.0) | 50 | 82±19 (0.8) | 98±37 (0.9) | |
| C + | 797±79 b | 1204±155e | 1193±39c | 1229±94 e | 1192±49d | 1804±43 e | C + | 716±74 b | 1636±162 e | |
a
Negative control: dimethylsulfoxide (DMSO - 100 µL/plate); C+ = Positive control -b4 -nitro-o-phenylenediamine (NOPD –10.0 µg/plate – TA98, TA97a);
c
sodium azide (1.25 µg/plate –TA100);
dc
mitomycin (0.5 µg/plate – TA102), in the absence of S9 and
e
2-anthramine (1.25 µg/plate – TA97a, TA98, TA100);
f
2-aminofluorene (10.0 µg/plate – TA102), in the presence of S9.